Y-Biologics Inc.

Yonsei University

Metabolic Engineering Laboratories Co., Ltd.

Seoul National University

Bum-chan Park

Young Woo Park

Seok Ho Yoo

Jae Eun Park

Seil Jang

Young-Gyu Cho

Jung Chae Lim

Si Hyung Lee

Gi Sun Baek

Hyun Mi Lee

Youngja Song

Yeung Chul Kim

Jisu Lee

Sang Pil Lee

Sunha Yoon

Ji-Young Shin

Yunseon Choi

Eun Young Lee

Dong Hee Lee

Yong Ho Lee

Soo Young Kim

Hee Chan Kim

Eun Bong Lee

Dong Jin Kim

Myeoung Hee Jang

Ji Su Lee

Jae Bong Yoon

Hyun Ju Lee

Joong Kyu Kim

Yeong Wook Song

Seon Ha Yun

Hye-Nan Kim

Bong-soo Cha

Heun-Soo Kang

Ki Chul Shin

So-Hyun Park

Ke Se Lee

Dong Jung Lee

Yeung-Chul Kim

Eun Young Jeon

Gisun Baek

Jin Chui Youn

Soo A Choi

Hyun Kyung Lee

Kyung Jin Kim

A bispecific antibody according to an embodiment of the present disclosure specifically binds to IL-17A and TNF-α. The bispecific antibody according to the present invention or an antigen binding fragment thereof exhibits high specificity for IL-17A and TNF-α and more favorable neutralization property compared to monospecific antibody of a prior art, and, by quickly suppressing inflammation and an immune response by inhibiting simultaneously IL-17 and TNF-α, it has an advantage of improving the treatment effect with lower dose.

Bispecific antibody specifically binding to IL-17A and TNF-α

A monoclonal antibody or an antigen-binding fragment thereof according to an embodiment of the present invention can bind to lymphocyte-activation gene 3 (LAG-3) including a heavy chain variable region and a light chain variable region and inhibit the activity thereof. Thus it is expected to be useful for the development of immunotherapeutic agents for various disorders that are associated with LAG-3.

Monoclonal antibody specifically binding to LAG-3 and use thereof

The present invention relates to an antibody against delta-like 1 homolog () (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.

Antibody against human DLK1 and use thereof

Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.

Antibody to programmed cell death 1 (PD-1) and use thereof

Disclosed are an antibody to human programmed cell death-ligand 1 (PD-L1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer or infectious diseases containing the same.

Antibody to programmed death-ligand 1 (PD-L1) and use thereof

The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL) regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv region so that the binding molecule binds to two different antigens.

Cell engaging binding molecules

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region. Also provided are health functional foods containing a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 (delta-like 1 homolog) or a fragment thereof with a human antibody Fc region as an active ingredient.

Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog

The present invention relates to a TNF-&#x3b1; (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-&#x3b1; specific antibody, is a bispecific antibody that effectively binds to both TNF-&#x3b1; and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-&#x3b1;/CXCL10. A composition of the present invention comprises a TNF-&#x3b1;/CXCL-10 double targeting antibody which effectively binds to both TNF-&#x3b1; and CXCL10. The double targeting antibody of the present invention has excellent TNF-&#x3b1; inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-&#x3b1; or CXCL10 single targeting antibody. The composition of the present invention can be used in preventing or treating immunological disease.

Anti-TNF-&#x3b1;/CXCL10 double-targeting antibody and use thereof

Growing community of inventors

Daejeon, South Korea

Bum-chan Park